Vaccine Therapy in Treating Patients With Metastatic Cancer
Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer
About this trial
This is an interventional treatment trial for Lung Cancer focused on measuring Ewing's family of tumors, adult soft tissue sarcoma, adult solid tumor, body system/site cancer, bone cancer, breast cancer, cancer, childhood cancer, childhood solid tumor, ciliary body and choroid melanoma, medium/large size, colon cancer, colorectal cancer, extraocular extension melanoma, eye cancer, female reproductive cancer, gastrointestinal cancer, genetic condition, intraocular melanoma, lung cancer, male breast cancer, melanoma, metastatic osteosarcoma, metastatic tumors of the Ewing's family, muscle cancer, musculoskeletal cancer, non-small cell lung cancer, osteosarcoma, osteosarcoma/malignant fibrous histiocytoma of bone, ovarian sarcoma, rectal cancer, recurrent adult soft tissue sarcoma, recurrent breast cancer, recurrent colon cancer, recurrent intraocular melanoma, recurrent melanoma, recurrent non-small cell lung cancer, recurrent osteosarcoma, recurrent rectal cancer, recurrent tumors of the Ewing's family, recurrent uterine sarcoma, skin tumor, solid tumor, stage IIIB, IV, recurrent, and metastatic breast cancer, stage IV adult soft tissue sarcoma, stage IV breast cancer, stage IV colon cancer, stage IV melanoma, stage IV non-small cell lung cancer, stage IV rectal cancer, stage IV uterine sarcoma, stage IVA adult soft tissue sarcoma, stage IVB adult soft tissue sarcoma, stage, Ewing's family of tumors, stage, adult soft tissue sarcoma, stage, breast cancer, stage, colon cancer, stage, intraocular melanoma, stage, melanoma, stage, non-small cell lung cancer, stage, osteosarcoma, stage, rectal cancer, stage, uterine sarcoma, thorax/respiratory cancer, uterine sarcoma
Eligibility Criteria
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically documented metastatic cancer of one of the following types: Cutaneous melanoma Ocular melanoma Colorectal carcinoma Non-small cell lung cancer Breast carcinoma Sarcoma HLA-Cw*0702 positive MAGE-12 expression by RT-PCR amplified tissue analysis Failed prior standard therapy Measurable or evaluable disease No renal carcinoma Hormone receptor status: Not specified --Prior/Concurrent Therapy-- Biologic therapy: At least 3 weeks since prior biologic therapy for cancer No other concurrent biologic therapy for cancer Chemotherapy: At least 3 weeks since prior chemotherapy for cancer and recovered No concurrent chemotherapy for cancer Endocrine therapy: At least 3 weeks since prior hormonal therapy for cancer No concurrent hormonal therapy for cancer No concurrent steroids Radiotherapy: At least 3 weeks since prior radiotherapy for cancer and recovered No concurrent radiotherapy for cancer Surgery: Prior surgery for cancer allowed --Patient Characteristics-- Age: 16 and over Sex: Male or female Menopausal status: Not specified Performance status: ECOG 0-2 Life expectancy: Greater than 3 months Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 90,000/mm3 Hepatic: Bilirubin no greater than 1.6 mg/dL AST/ALT less than 3 times normal Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No cardiac ischemia, myocardial infarction, or cardiac arrhythmias (if receiving interleukin-2 (IL-2) therapy) Pulmonary: No obstructive or restrictive pulmonary disease (if receiving IL-2 therapy) Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception No active systemic infections No autoimmune disease, known immunodeficiency disease, or active primary or secondary immunodeficiency Hepatitis B surface antigen negative HIV negative No other active major medical illnesses (if receiving IL-2 therapy)
Sites / Locations
- Surgery Branch